Valeant and Allergan's wining-and-dining shows pharma's faith in doctor influence

Payers may be grabbing the spotlight as script gatekeepers, but if the recently concluded takeover fight between Valeant ($VRX) and Allergan ($AGN) is any indication, doctors are still extremely influential--and companies still believe they can be influenced. Report

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.